Prop. 71's fine print contains surprises: Tightly written law leaves little room for oversight or changes
By Bernadette Tansey,
San Francisco Chronicle
| 12. 08. 2004
The $3 billion stem cell initiative that passed overwhelmingly last month holds surprises for voters who didn't read it -- starting with a provision that the research money doesn't have to be spent on stem cell studies.
It's also not the case, contrary to campaign pitches for Proposition 71, that the $3 billion raised from state bonds won't cost the state anything for the first five years. Interest payments will begin immediately, paid out of the bond money itself -- meaning that tens to hundreds of millions of "research" dollars must be used to pay debt service.
And as lawmakers and critics have learned, if they find fault with the ballot initiative, changing it could be tough. Under the proposition's terms, the state Legislature can't modify the law for three years. Even then, it can do so only by a 70 percent vote of both houses and with the governor's approval.
Some laws are like a car patched together from spare parts, but the California Stem Cell Research and Cures Initiative is built like a tank. Lawyers involved in...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...